Niraparib + Dostarlimab + RT in Pancreatic Cancer

Pancreatic Cancer Clinical Trial

Official title:

A Phase II Study of Niraparib and Dostarlimab With Radiation in Patients With Metastatic Pancreatic Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04409002
• Other study ID #: 19-538
• Status: Completed
• Phase: Phase 2
• Start date: July 23, 2020
• Est. completion date: February 25, 2022

Study information

• Verified date: June 2023
• Source: Massachusetts General Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This research is being done to see how the combination of dostarlimab, niraparib, and radiation therapy works in controlling metastatic pancreatic cancer.

Description:

This two-stage single arm phase II trial will evaluate the efficacy of niraparib with dostarlimab and radiation therapy in patients with metastatic pancreatic cancer

The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.

The names of the experimental interventions involved in this study are:

• Dostarlimab

• Niraparib

• Radiation Therapy

It is expected that about 25 people will take part in this research study. An initial 15 participants will be enrolled during the first stage and evaluated for treatment disease control, if none of the initial 15 participants achieve disease control the study will be terminated.

It is expected participants will be on the research study for as long as the experimental interventions are safe, and their metastatic pancreatic cancer does not progress with up to 5 years of follow up after participants stop taking the experimental interventions.

This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational intervention to learn whether the intervention works in treating a specific disease. "Investigational" means that the intervention is being studied.

The U.S. Food and Drug Administration (FDA) has not approved dostarlimab as a treatment for any disease. Dostarlimab is a type of antibody (a protein that attaches to other cells to fight off infection) that is believed to work by attaching to a protein called PD-1 on Tcells.

This PD-1 protein controls parts of the immune system (the system in the body that fights off infections and diseases) by shutting down certain immune responses responsible for recognizing and destroying cancer cells. The investigators believe that dostarlimab will inhibit the PD-1 protein, thus allowing the immune cells to recognize and destroy cancer cells. The FDA has not approved niraparib for metastatic pancreatic cancer, but it has been approved for other uses. Niraparib is a type of drug called a "PARP inhibitor", which blocks DNA (the genetic material of cells) damage from being repaired or may prevent damage from occurring in the first place. In cancer treatment, inhibiting PARP may help kill cancer cells by not allowing the cancer cells to repair its DNA damage or prevent DNA damage from occurring. It is believed that the combination of dostarlimab, niraparib, and radiation therapy may have a greater effect on metastatic pancreatic cancer cells than when these interventions are used alone.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 18
• Est. completion date: February 25, 2022
• Est. primary completion date: January 19, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically or cytologically confirmed metastatic adenocarcinoma of pancreatic origin.

• Age > 18 years.

• ECOG performance status = 1.

• Life expectancy of greater than 3 months.

• Participants must have normal organ and marrow function as defined below:

• leukocytes = 2,000/mcL

• absolute neutrophil count = 1,500/mcL

• platelets = 100,000/mcL

• hemoglobin = 9 g/dL

• AST(SGOT)/ALT(SGPT) =2.5 × institutional upper limit of normal(subjects with liver metastases can have an AST (SGOT) = 5 x ULN

• creatinine = 1.5 x ULN OR

• creatinine clearance* = 60 mL/min (if using the Cockcroft-Gault formula)

• total bilirubin = 1.5 x ULN (subjects with Gilbert Syndrome can have a total bilirubin < 3 x ULN)

• INR, PT, aPTT = 1.5 x ULN (subjects receiving anticoagulant therapy must have PT or PTT within therapeutic range) *Creatinine clearance should be calculated per the following: CrCl (mL/min) = (140 - age [years]) x weight [kg] x 1.23 (x 0.85 if female)/ Serum creatinine (micromol/L)

• Women of childbearing potential (WoCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 7 days prior to initiating protocol therapy.

Non childbearing potential is defined as follows (by other than medical reasons):

• =45 years of age and has not had menses for >1 year

• Patients who have been amenorrhoeic for <2 years without history of a hysterectomy and oophorectomy must have a follicle stimulating hormone value in the postmenopausal range upon screening evaluation

• Post-hysterectomy, post-bilateral oophorectomy, or post-tubal ligation. Documented hysterectomy or oophorectomy must be confirmed with medical records of the actual procedure or confirmed by an ultrasound. Tubal ligation must be confirmed with medical records of the actual procedure, otherwise the patient must be willing to use 2 adequate barrier methods throughout the study, starting with the screening visit through 150 days after the last dose of study treatment. See Section 4.4 for a list of acceptable birth control methods. Information must be captured appropriately within the site's source documents. Note: Abstinence is acceptable if this is the established and preferred contraception for the patient.

• Women of childbearing potential must agree to use appropriate method(s) of contraception. WOCBP should use an adequate method to avoid pregnancy for 6 months (30 days plus the time required for niraparib to undergo five half-lives/150 days) after the last dose of investigational drug.

• Women must not be breastfeeding during the study or for 150 days after the last dose of investigational drug.

• Men who are sexually active with WoCBP must use any contraceptive method with a failure rate of less than 1% per year. Men receiving protocol therapy and who are sexually active with WoCBP will be instructed to adhere to contraception for a period of 6 months (150 days) after the last dose of investigational product. (Women who are not of childbearing potential, i.e. are postmenopausal as defined in the eligibility criteria or surgically sterile, as well as azoospermic men do not require contraception.) Ability to understand and the willingness to sign a written informed consent document

• If applicable, stable dose of dexamethasone of 10mg or less for 4 weeks prior to initiation of investigational protocol therapy. Regimen must be completed >14 days prior to treatment start.

• One previously unirradiated lesion amenable to radiotherapy at a dose of 8 Gy x 3 and can meet dose constraints, and another unirradiated measurable lesion > 1 cm in size outside the radiation field that can be used as measurable disease.

• Patients must have had at least one line of prior treatment. Any prior line of treatment is permitted, including adjuvant.

Exclusion Criteria:

Participants who meet any of the following criteria will be excluded:

• Systemic anticancer or biological therapy including prior chemotherapy, immunotherapy, targeted small molecule therapy within 14 days prior to investigational agent, or those who have not recovered (i.e., = grade 1 or at baseline) from adverse events due to agents administered more than 2 weeks earlier. Participants with = grade 2 neuropathy are an exception to these criteria and may qualify for the study. If the participant received major surgery, then they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.

• Received investigational therapy = 4 weeks, or within a time interval less than at least 5 half-lives of the investigational agent, whichever is shorter, prior initiating protocol therapy.

• Major surgery = 3 weeks prior to initiating protocol therapy and/or not recovered from any surgical effects.

• Received radiation therapy encompassing >20% of the bone marrow within 2 weeks; or any radiation therapy within 1 week prior to day 1 of protocol therapy.

• Received a transfusion (platelets or red blood cells) = 4 weeks prior to initiating protocol therapy

• Received colony-stimulating factors (e.g., granulocyte colony-stimulating factor, granulocyte macrophage colony-stimulating factor, or recombinant erythropoietin) within 4 weeks prior to initiating protocol therapy. Known history of Grade 3 or 4 anemia, neutropenia or thrombocytopenia due to prior chemotherapy that persisted > 4 weeks and was related to the most recent treatment.

• Known history of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).

• Active, known or suspected autoimmune disease that has required systemic treatment within the past 2 years other than vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger.

• Any condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease. Participants are permitted to use topical, ocular, intraarticular, intranasal, and inhalational corticosteroids (with minimal systemic absorption). Physiologic replacement doses of systemic corticosteroids are permitted, even if > 10 mg/day prednisone equivalents. A brief course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergen) is permitted.

• Known history of active TB (Bacillus Tuberculosis). Testing is not required for eligibility purposes.

• Known hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic infection. Testing is not required for eligibility purposes.

• Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS). These participants are at increased risk of lethal infections when treated with marrow suppressive therapy. Testing is not required for eligibility purposes.

• Known = Grade 3 immune-related AE with prior immunotherapy, with the exception of non-clinically significant lab abnormalities.

• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, recent (within 90 days) myocardial infarction or psychiatric illness/social situations that would limit compliance with study requirements.

• Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.

• Known additional malignancy diagnosed, detected or treated = 2 years prior to initiation of protocol therapy . Exceptions include basal cell carcinoma of the skin and squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer.

• Known history of, or any evidence of active, non-infectious pneumonitis or interstitial lung disease.

• Active infection requiring systemic therapy

• Has received a live vaccine within 30 days of planned start of study therapy. Note:

Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines, and are not allowed.

• Known hypersensitivity to niraparib and dostarlimab components or excipients.

• History of severe hypersensitivity reaction to any monoclonal antibody

• Participants with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.

Further imaging is not required for eligibility purposes.

Related Conditions & MeSH terms

• Metastatic Pancreatic Cancer
• Pancreatic Cancer
• Pancreatic Neoplasms

Intervention

Drug:
• Niraparib
Niraparib oral, once a day, predetermined dose.Dosing will commence on cycle 1 day 1 and will continue until the participant is taken off treatment
• Dostarlimab
Dostarlimab by intravenous infusion once every cycle for as long as they remain on the study

Radiation:
• Radiation
Radiation therapy on every other week day of cycle 2 only. Radiation will begin on Cycle 2 Day 1

Locations

Country	Name	City	State
United States	Massachusetts General Hospital Cancer Center	Boston	Massachusetts

Sponsors (2)

Lead Sponsor	Collaborator
Massachusetts General Hospital	Tesaro, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Disease Control Rate With RECIST 1.1 Criteria	Disease control rate (DCR) is the percentage of participants who experienced a complete response (CR), partial response (PR), or stable disease (SD) assessed by the Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 criteria below.; CR = Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm.; PR = At least 30% decrease in the sum of longest diameters of target lesions, taking as reference the baseline sum diameters.; SD = Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the baseline sum diameters while on study.; Progressive Disease (PD) = At least 20% increase in the sum of longest diameters of target lesions, taking as reference the baseline sum diameters while on study. Appearance of one or more new lesions is also considered progression.	up to 17 months
Secondary	Disease Control Rate With irRECIST Criteria	Disease control rate (DCR) is the percentage of participants who experienced a immune-related complete response (irCR), partial response (irPR), or stable disease (irSD) assessed by the Immune-Related Response Evaluation Criteria In Solid Tumors (irRECIST) criteria below.; irCR = Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm.; irPR = At least 30% decrease in the sum of longest diameters of target lesions, compared to baseline.; irSD = Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, compared to baseline.; Immune-related Progressive Disease (irPD) = At least 20% increase in the sum of longest diameters of target lesions AND at least 5mm absolute increase, compared to baseline. Appearance of one or more new lesions is also considered progression. Confirmation scan required at least 4 weeks later.	up to 17 months
Secondary	Progression-free Survival	Progression-free survival (PFS) is defined as the time duration from the first day of protocol treatment to the earlier date of disease progression or death due to any cause. PFS time will be censored at the date of last follow-up for surviving patients with disease control.	up to 17 months
Secondary	Overall Survival	Overall survival (OS) is defined as the time duration from the first day of protocol treatment to the date of death due to any cause, and will be censored at the date of last follow-up for patients still alive.	up to 17 months
Secondary	Number of Treatment-Related Adverse Events Per CTCAE v5.0	Treatment-related adverse events (TRAEs) are evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE) v5.0, as grades 3-5 and at least possibly attributed to study treatment. TRAEs are evaluated from the start of study treatment through 30-days after the last treatment dose.	up to 19 weeks